Press Releases

Q1 2011: achievement of key milestones in BioAlliance Pharma’s clinical development program

Recurring revenue streams reflect the international deployment of Loramyc® BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today reported a consolidated turnover of €604,000 for the first quarter of 2011. This turnover is constituted for €560,000 of recurring revenues from licensing agreements for Loramyc®. These revenues are similar…read more →

BioAlliance Pharma expands its Loramyc® franchise in Japan

with Sosei in a deal valued up to 18.5M$ BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. (a wholly owned subsidiary of Sosei Group Corporation – TSE Mothers Index: 4565) for commercialization rights…read more →

BioAlliance Pharma accelerates its European clinical development of clonidine Lauriad™

The product becomes part of the Company’s Orphan Oncology Business Unit BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced the extension of its ongoing clonidine Lauriad™ phase II clinical trial in chemoradiation therapy induced oral mucositis in patients with head and neck cancer to Germany…read more →

Publication of the 2010 Annual Report

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced that its 2010 Annual Report, in its capacity as Reference Document, was registered with the French Market Authorities on April 7, 2011. It is available free of charge to the public upon request as per current legal regulations at…read more →

Livatag® (Doxorubicin Transdrug™) follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the update of its preliminary positive survival data with Livatag® (doxorubicin Transdrug™). Livatag® is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. Livatag® was granted an orphan drug status in Europe and in the United…read more →

BioAlliance Pharma receives €2 million in funding for peptide applications of the patented LauriadTM mucoadhesive technology

BioAlliance is capitalizing on its mucosal know-how BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma….read more →

BioAlliance Pharma appoints Judith Greciet Deputy Chief Operating Officer

Experienced pharma industry executive, Judith Greciet brings robust performance record to an Innovation Company BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced that it has strengthened its management team with the appointment of Judith Greciet as Deputy Chief Operating Officer, in charge of Operations and R&D. Judith Greciet joins…read more →

Consolidated turnover for 2010

Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a consolidated turnover for 2010 of €22.5 million – up from €7.5 million in 2009. This exceptional performance was due to the sales and licensing agreements implemented for Loramyc® (Oravig® in the United States)….read more →

BioAlliance Pharma presents the results of an international survey performed with Nielsen in patients suffering from herpes labialis

BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, has presented the preliminary results of a study in patients suffering from herpes labialis in the United States and Europe. Given that treatment with Sitavir® (acyclovir Lauriad™) has proven efficacy in recurrent herpes labialis, the company considered it was important to better understand…read more →

BioAlliance Pharma announces new opportunities for its Patented Lauriad™ mucoadhesive technology

New collaborative programs BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both “Clusters of excellence”, Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects…read more →

BioAlliance Pharma presents preclinical and phase I clinical results with its AMEP® biotherapy for metastatic melanoma

At the “Electrochemotherapy 1st International Users’ Meeting” (Bologna, Italy, November 19-20, 2010) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP® biotherapy at the “Electrochemotherapy 1st International Users’ Meeting” (Bologna, Italy, November 19-20, 2010). The AMEP® biotherapy is…read more →

BioAlliance Pharma presents pharmacokinetic results of its Sitavir® (acyclovir Lauriad®)

At the FIP Pharmaceutical Sciences World Congress (PSWC) 2010 in association with the AAPS Annual Meeting and Exposition (November 14-18, 2010, New Orleans, Louisiana, USA) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, presented the results of the pharmacokinetic study on its Sitavir® (acyclovir Lauriad® 50mg), developed for the…read more →

The structure of BioAlliance Pharma’s turnover for Q3 2010 reflects the dynamism of the company’s American and European collaborations

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a consolidated turnover of €0.9 million for the third quarter of 2010. This recurrent turnover mainly corresponds to revenues received for Loramyc®/Oravig® sales by the company’s international licensing partners. In line with the announcements made in late August, Oravig®…read more →

Dismissal of the civil action filed by Eurofins against BioAlliance in the United States confirmed by the US court of appeals

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, announces that the United States Court of Appeals for the Third Circuit has confirmed the Federal District Judge’s dismissal of the US civil action filed by Eurofins against BioAlliance Pharma and one of its former executives. In addition to finding that…read more →

BioAlliance Pharma will participate in BioPartnering EuropeTM Conference (London, 10-12 October, 2010)

BioAlliance Pharma SA (Euronext Paris -BIO), a company dedicated to the supportive care and treatment of cancer patients, will participate in the 18th BioPartnering EuropeTM Conference (London, 10-12 October, 2010). This international annual conference is dedicated to meetings between the various players in the pharma/biotech area. BioAlliance’s management team will present its development strategy and the significant advances that were…read more →